MENU

Codexis ECO Synthesis: 100g Scale Performance and siRNA Specs

Markets Insider(GlobeNewswire / Codexis) USA
Overview
Codexis presented data at TIDES Europe 2026 showing its ECO Synthesis platform achieves over 90% product quality at a 100-gram scale while nearly halving cycle time. The platform also demonstrated a 3- to 4-fold increase in potency in human hepatocyte in vitro models compared to traditional chemical synthesis. These results indicate a scalable, enzymatic alternative to solid phase organic synthesis for RNAi therapeutics.
In Depth

Key Findings

Codexis has demonstrated the scalability and quality of its ECO Synthesis Manufacturing Platform at a 100-gram scale. Data presented at TIDES Europe 2026 show that the platform achieves product quality exceeding 90% and has nearly halved cycle times. This level of performance and quality was maintained consistently across three orders of magnitude in scale.

Technical Details

The ECO Synthesis platform enables precise control over siRNA stereochemistry and the efficient incorporation of tissue-targeting moieties. In an ongoing structure-activity relationship (SAR) study, Codexis compared material produced via ECO Synthesis against identical siRNA synthesized using traditional chemical methods. The results showed a 3- to 4-fold increase in potency within human hepatocyte in vitro models for the enzymatically synthesized material with defined phosphorothioate stereochemistry.

Background and Context

ECO Synthesis is an aqueous enzymatic process designed as a scalable alternative to traditional solid phase organic synthesis for oligonucleotide manufacturing. Codexis is currently applying this technology to the RNAi therapeutics market. The company’s proprietary enzymes are intended to provide several operational advantages over traditional methods, including:

  • Higher yields and increased purity.
  • Reduced energy usage and waste generation.
  • Stereoisomer control of siRNA.
  • Lower capital requirements for manufacturing capacity.

Significance and Outlook

The ability to maintain quality at the 100-gram scale, combined with the capacity for stereochemical control and targeted delivery, moves the ECO Synthesis platform toward industrial adoption readiness. By enabling molecular precision and improved manufacturing efficiency, the platform provides tools to optimize the design and performance of next-generation RNA therapeutics. Codexis continues to refine the process to increase productivity as it advances toward full industrialization.

Source: https://markets.businessinsider.com/news/stocks/codexis-advances-eco-synthesis-toward-adoption-readiness-with-quality-at-scale-and-expanded-sirna-manufacturing-capabilities-1036736462

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC